-
Mashup Score: 0Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction - 1 year(s) ago
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder resulting from the loss of expression of maternally imprinted genes located in the paternal chromosomal region, 15q11–13. Impaired hypothalamic development and function is the cause of most of the phenotypes comprising the developmental trajectory of Prader-Willi syndrome: from anorexia at birth to excessive weight gain preceding…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction - 1 year(s) ago
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder resulting from the loss of expression of maternally imprinted genes located in the paternal chromosomal region, 15q11–13. Impaired hypothalamic development and function is the cause of most of the phenotypes comprising the developmental trajectory of Prader-Willi syndrome: from anorexia at birth to excessive weight gain preceding…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome. These results support the use of setmelanotide and provided the necessary evidence for approval of this drug as the first treatment for obesity in patients with Bardet-Biedl syndrome.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
In The Lancet Diabetes & Endocrinology, Andrea Haqq and colleagues1 report on the safety and efficacy of setmelanotide at 52 weeks in patients with Bardet-Biedl syndrome and Alström syndrome in a phase 3, open-label trial with an initial, randomised, double-blind, placebo-controlled period.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 4Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction - 1 year(s) ago
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder resulting from the loss of expression of maternally imprinted genes located in the paternal chromosomal region, 15q11–13. Impaired hypothalamic development and function is the cause of most of the phenotypes comprising the developmental trajectory of Prader-Willi syndrome: from anorexia at birth to excessive weight gain preceding…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome. These results support the use of setmelanotide and provided the necessary evidence for approval of this drug as the first treatment for obesity in patients with Bardet-Biedl syndrome.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
In The Lancet Diabetes & Endocrinology, Andrea Haqq and colleagues1 report on the safety and efficacy of setmelanotide at 52 weeks in patients with Bardet-Biedl syndrome and Alström syndrome in a phase 3, open-label trial with an initial, randomised, double-blind, placebo-controlled period.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
In The Lancet Diabetes & Endocrinology, Andrea Haqq and colleagues1 report on the safety and efficacy of setmelanotide at 52 weeks in patients with Bardet-Biedl syndrome and Alström syndrome in a phase 3, open-label trial with an initial, randomised, double-blind, placebo-controlled period.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 4The Lancet Diabetes & Endocrinology, December 2022, Volume 10, Issue 12, Pages 827-900 - 1 year(s) ago
Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and metabolism
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome. These results support the use of setmelanotide and provided the necessary evidence for approval of this drug as the first treatment for obesity in patients with Bardet-Biedl syndrome.
Categories: Endocrinology, Latest HeadlinesTweet
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat #hypothalamic dysfunction https://t.co/ApVUI4MIbR #praderwilli #pws #hyperphagia #obesity https://t.co/JIXLH1tBwA